After offering a deep dive last year into the recipe behind its lead lung fibrosis candidate, Insilico Medicine is now giving ...

The MAD cohort also saw adverse events such as hair loss and reductions in hemoglobin and neutrophil counts. These side ...

Inventiva is going all-in on its metabolic-associated steatohepatitis (MASH) drug lanifibranor —but half of its employees won ...

Incyte has broken off its immuno-oncology deal with Agenus. The step, which follows a series of program terminations, will ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...

Tasso, the maker of at-home blood sample collection systems, is launching the next generation of its devices that aim to support patients enrolled in clinical trials and simplify their pa | Its ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

This article was updated at 1 p.m. ET  to include new information about the lawsuit against the NIH. | A new initiative ...

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...